If you have ever told a patient to call 1300 MEDICINE when a medication question came up outside of a consultation — or used it yourself to report an adverse drug or vaccine reaction — that option disappears at the end of July.

The 1300 MEDICINE helpline — pharmacist-staffed, averaging 900 calls a month — closes permanently on 30 July 2026. The service was contracted to Australian Healthcare Associates following the closure of NPS MedicineWise in December 2022. That contract ends. There is no announced replacement.

The timing is worth paying attention to because medication queries do not follow business hours, and the patient population most likely to call a phoneline for medication advice — older people managing multiple medicines, carers coordinating complex regimens, people newly started on something unfamiliar — are also those least able to navigate digital alternatives.

What the service did

1300 MEDICINE offered two things: pharmacist-staffed medication advice accessible to consumers, and a reporting pathway for adverse reactions to medications and vaccines.

The advice function was the more-used service: the line averaged 900 calls per month, with a historical annual volume of 7,000 to 10,000 calls. These are patients — and sometimes clinicians — with medication questions about interactions, side effects, and dosing queries that arose outside of a pharmacy or GP consultation window.

The adverse reaction reporting function was the less-visible but potentially more consequential one. Australia’s pharmacovigilance signal detection depends in part on consumer and clinician reporting to the TGA. A dedicated phoneline that accepted those reports — and translated consumer calls into structured TGA notifications — provided accessible reporting infrastructure for people who would not otherwise navigate a regulator’s website.

That second function now falls to the TGA directly, which has its own reporting mechanisms. The question is whether consumers who would have called 1300 MEDICINE will instead navigate the TGA portal, and whether the friction of that step reduces reporting uptake.

The stated rationale

The Department of Health’s position is that the closure reflects a broader approach to strengthening general practice — the idea being that directing patients toward GPs, pharmacists, and nurse practitioners who know their medical history produces better outcomes than a generic phone consultation.

That framing is not wrong. Continuity of care is a real value. A pharmacist who knows your medicines and your context is better placed to advise than an anonymous line. RACGP Deputy Chair Dr Michael Bonning acknowledged the service “has been a genuine help to a small group” while emphasising the need to ensure nobody falls through gaps.

The question the department’s framing does not fully answer is: what happens in the scenario the line was specifically designed for? The patient who calls at 8 pm with a question about whether two newly dispensed medicines interact. The older person whose GP is on leave and whose pharmacist is closed. The carer who wants to report a reaction but does not know how to submit a TGA form online.

Both-and

The service was small at 900 calls per month. Scaled to a population of 26 million, it is not the backbone of medication safety — it is a niche resource. The department is right that most medication questions can and should be resolved through the patient’s existing care relationships.

The argument for preserving it was not scale but coverage — the cases that fall outside normal care touchpoints. Whether that gap is better filled by improving after-hours access to community pharmacists and GPs depends on whether those alternatives are actually accessible when the question arises. In many parts of Australia, the answer to that is uncertain.

The adverse reaction reporting dimension is where the policy rationale is thinnest. Pharmacovigilance signal detection benefits from volume and accessibility. A phoneline that converted consumer calls into structured TGA notifications served a data-gathering function that directing people to a website does not equivalently replace — not because the website is inadequate, but because a proportion of callers will not make it through the digital steps.

My two cents

If you have patients who might reach for 1300 MEDICINE, it is worth having the conversation before 30 July. The practical alternatives:

Community pharmacist — the best first stop for medication questions, including after-hours pharmacies in most urban and regional centres.
1800 MEDICARE — available for administrative queries, though not for clinical medication advice.
TGA adverse event reporting — the TGA’s online and phone reporting channels for consumers and health professionals reporting adverse drug or vaccine reactions. The TGA reporting pathway is at tga.gov.au/reporting-problems.
Your GP — for queries that arise in the context of current prescriptions, within consultation hours.

The adverse reaction reporting pathway is the one most worth making explicit to patients who might not know to contact the TGA directly. The signal detection value of consumer-reported reactions is real, and the friction of going to a regulator’s website rather than calling a number is not trivial for some patient groups.

General practice does not need to absorb this work. But knowing the landscape has changed from 30 July is useful context for the conversations that will follow.

Verdict: yes — a service closure that changes patient navigation for medication queries and adverse reaction reporting from 30 July 2026.

Sources cited

Medications advice phoneline to close — newsGP, June 2026